Therefore, LINC00520-mediated inhibition of EGFR suppresses the PI3K/AKT signaling pathway by preventing the progression, invasiveness, and migration of CSCC cells in vitro and by reducing tumor growth and metastasis in vivo [37].These findings suggest LINC00520 as a new potential therapeutic target for novel therapeutic approaches in the CSCC. The gene discussed is AKT1; the disease is neoplasm.